← Back to Guidelines

2019 ACC/AHA Primary Prevention of Cardiovascular Disease

Clinical Quick Reference — Comprehensive Prevention Strategies for ASCVD

Published: Journal of the American College of Cardiology (2019)
Societies: American College of Cardiology / American Heart Association
DOI: 10.1016/j.jacc.2019.03.010
View Full Guideline PDF

Top 10 Take-Home Messages

  1. Lifestyle is foundational: The most important way to prevent ASCVD is to promote a healthy lifestyle throughout life (diet, physical activity, weight management, tobacco cessation).
  2. Risk-based decision-making: For adults 40–75 years, routinely assess traditional cardiovascular risk factors and calculate 10-year ASCVD risk using the Pooled Cohort Equations (PCE) or alternative calculators.
  3. Statin therapy is first-line: In intermediate-risk (7.5%–<20%) and high-risk (≥20%) adults, statin therapy reduces ASCVD events and mortality. Risk-enhancing factors support statin use in borderline-risk (5%–<7.5%) patients.
  4. Risk stratification thresholds: Low <5%, Borderline 5–<7.5%, Intermediate 7.5–<20%, High ≥20% 10-year ASCVD risk.
  5. Aspirin selectively: Aspirin should be used infrequently in primary prevention, generally limited to high-risk adults (≥20% 10-year risk) after individual risk-benefit discussion.
  6. Blood pressure targets: Adults with ASCVD risk ≥10% should target <130/80 mmHg. Those with lower risk can target <140/90 mmHg with lifestyle optimization first.
  7. Physical activity essentials: Adults should engage in ≥150 minutes per week of moderate-intensity activity OR ≥75 minutes per week of vigorous-intensity activity.
  8. Diabetes management: For adults with type 2 diabetes, initiate metformin as first-line along with lifestyle modification. Consider GLP-1 RA or SGLT2i for CV risk reduction when indicated.
  9. Shared decision-making: Decisions about preventive interventions should involve collaboration between clinicians and patients, considering values, preferences, and absolute risk.
  10. Social determinants matter: Socioeconomic inequalities are strong determinants of ASCVD risk; treatment recommendations should be tailored to individual circumstances.

Overview & Rationale

This 2019 guideline represents the most comprehensive ACC/AHA consensus on primary prevention of atherosclerotic cardiovascular disease (ASCVD). The evidence base emphasizes:

Core Prevention Principles:
  • A team-based care approach involving physicians, nurses, pharmacists, and other health professionals
  • Shared decision-making informed by absolute risk estimates and patient preferences
  • Lifestyle optimization as the foundation for all ASCVD prevention
  • Pharmacotherapy tailored to individual risk, starting with statins when indicated
  • Attention to social determinants and health equity

Target Population: Adults ages 20–79 without established ASCVD, with emphasis on ages 40–75 for risk calculation and treatment decisions.

ASCVD Risk Assessment & Calculation

Risk Stratification Algorithm

10-Year ASCVD Risk Categories (Pooled Cohort Equations)

Low Risk: <5% 10-year ASCVD risk → Encourage healthy lifestyle, reassess periodically
Borderline Risk: 5%–<7.5% 10-year ASCVD risk → Consider risk-enhancing factors; shared decision-making for statin initiation
Intermediate Risk: 7.5%–<20% 10-year ASCVD risk → Statin therapy reduces events; CAC scoring may refine risk
High Risk: ≥20% 10-year ASCVD risk → Initiate statin + lifestyle; consider intensive therapy

When to Calculate Risk

Calculate Risk in:

  • All adults ages 40–75 years at the first healthcare encounter, then every 4–6 years
  • Adults 20–39 years with family history, diabetes, hypertension, or lipid abnormalities
  • Before starting preventive pharmacotherapy
  • When treatment decisions are uncertain (e.g., borderline risk)

Risk-Enhancing Factors

These factors, even if not included in the PCE, favor statin initiation or more aggressive management in borderline or intermediate-risk patients:

Factor Category Specific Risk-Enhancers
Lipid Markers LDL-C ≥160 mg/dL; Lipoprotein(a) ≥50 mg/dL; Non-HDL-C ≥190 mg/dL
Metabolic Metabolic syndrome; Prediabetes (glucose 100–125 mg/dL or HbA1c 5.7%–6.4%); Type 2 diabetes
Blood Pressure Hypertension (SBP ≥160 or DBP ≥100 mmHg, or on therapy)
Renal eGFR <60 mL/min/1.73m²; Albuminuria (UACR ≥30 mg/g)
Inflammatory High-sensitivity CRP (hsCRP) ≥3 mg/L
Lifestyle Current smoking; Sedentary lifestyle; Low cardiorespiratory fitness
Demographic Male sex; Premature menopause (before age 40); South Asian ancestry
Family History Premature ASCVD (male <55 years, female <65 years)
Other HIV; Chronic kidney disease; Rheumatoid arthritis; Systemic lupus erythematosus

Coronary Artery Calcium (CAC) Scoring

2a For intermediate-risk (7.5%–<20%) or selected borderline-risk (5%–<7.5%) adults where treatment decisions are uncertain, CAC scoring may refine risk estimation:

Risk Calculator Tools

Use these online tools for convenient risk calculation:

Pooled Cohort ASCVD Risk

10-year ASCVD event risk using original PCE equations

PREVENT-ASCVD

Newer equations; ages 30–79 with additional risk factors

MESA Risk Score

Multi-Ethnic Study of Atherosclerosis risk stratification

Framingham Risk Score

10-year general cardiovascular risk assessment

Lifestyle Interventions

Healthy Diet Patterns

1 A diet emphasizing vegetables, fruits, legumes, nuts, whole grains, and fish is recommended to reduce ASCVD risk.

Recommended Patterns:
  • Mediterranean Diet: Olive oil, vegetables, fruits, nuts, legumes, and fish. ~30% ASCVD risk reduction in high-risk populations (PREDIMED trial).
  • DASH Diet: Vegetables, fruits, whole grains, lean proteins, low sodium. Reduces BP by 8–11 mmHg systolic.
  • Plant-Based Diets: Vegetarian and vegan patterns associated with lower all-cause mortality and CV events.

Dietary Modifications

Dietary Component Recommendation Evidence
Saturated Fat 2a <7% of total calories Reduces LDL-C and ASCVD events
Trans Fat 1 Avoid completely Strongly associated with ASCVD; no safe level
Dietary Cholesterol 2a <200 mg/day Modest LDL-C reduction
Sodium 2a <2,300 mg/day; goal <1,500 mg/day Reduces BP and ASCVD risk
Refined Carbs 2a Minimize added sugars and refined grains Associated with weight gain and CV events
Processed Meats 2a Minimize; prefer fish and plant proteins Processed meat associated with ASCVD mortality
Whole Grains ≥50% of grains; 25–30 g fiber/day Improves lipids, BP, weight; lowers CV risk
Nuts & Legumes 1 ounce nuts daily or legumes ≥4 times/week Reduces CV events; improves lipid profile

Physical Activity

1 Adults should be routinely counseled to optimize a physically active lifestyle. Specific target:

Physical Activity Recommendations

Moderate-Intensity: ≥150 minutes per week (brisk walking, cycling, recreational sports)
Vigorous-Intensity: ≥75 minutes per week (jogging, competitive sports, aerobic dancing)
Combination: Mix moderate and vigorous activity; even some activity is better than none
Resistance Training: 2 days per week for weight and strength maintenance
Sedentary Behavior: 2a Decrease sitting time; break up prolonged sedentary periods

Key Evidence: Strong, graded dose–response relationship between physical activity and ASCVD risk reduction. Maximum benefit at ~1,000 kcal/week of activity.

Weight Management

1 In individuals with overweight and obesity, weight loss is recommended to improve ASCVD risk factors.

Weight Loss Targets & Strategies:
  • Goal: 5–10% initial weight loss provides clinically meaningful improvements in BP, lipids, and glucose
  • Comprehensive Lifestyle: Calorie restriction (500–1,000 kcal/day deficit) + ≥150 min/week activity + behavioral counseling
  • Medical Supervision: For intensive programs or those with comorbidities
  • BMI Monitoring: 1 Calculate annually to identify overweight (BMI 25–29.9) or obesity (BMI ≥30)
  • Waist Circumference: 2a Measure to identify increased cardiometabolic risk (men >40", women >35")
💡 Pearl: Even 5% weight loss can reduce hypertension risk, improve insulin sensitivity, and decrease triglycerides. Moderate weight loss in obese individuals improves CV outcomes significantly.

Tobacco Cessation

1 Smoking cessation is critical. All smokers should be counseled and offered pharmacotherapy as comprehensive management.

Evidence for Cessation Benefit

Pharmacotherapy Options

Agent Dose / Duration Mechanism Efficacy
Varenicline (Chantix) Titrate to 1 mg PO BID × 11–24 weeks Partial α4β2 nicotine receptor agonist ~35% abstinence at 1 year (highest)
Bupropion (Wellbutrin SR) 150 mg PO BID × 7–12 weeks Dopamine/norepinephrine reuptake inhibitor ~30% abstinence at 1 year
Nicotine Replacement Therapy (NRT) Patch ± gum, nasal spray, lozenge × 8–12 weeks Nicotine agonist via non-smoking route ~15–25% abstinence; often combined with other agents
Combination Therapy NRT patch + another formulation (gum, lozenge, spray) Sustained + bolus nicotine delivery ~40% abstinence (higher than monotherapy)

Counseling & Behavioral Support

Pharmacotherapy + counseling yields best outcomes:

❌ Don't:

  • Recommend e-cigarettes as cessation aids (insufficient CV benefit evidence)
  • Delay pharmacotherapy awaiting "motivation"—provide medication + support simultaneously
  • Ignore second-hand smoke exposure in family members

Statin Therapy for Primary Prevention

Statin Therapy Decision Algorithm

1 Statin therapy is first-line treatment for primary prevention in ASCVD risk-based groups. The following algorithm guides initiation:

Statin Therapy Selection by 10-Year ASCVD Risk

HIGH RISK: ≥20% 10-year ASCVD

Recommendation: 1 Initiate high-intensity statin therapy for all
LDL-C Goal: Reduce by ≥50% from baseline; target <70 mg/dL
High-Intensity Agents: Atorvastatin 40–80 mg or Rosuvastatin 20–40 mg daily

INTERMEDIATE RISK: 7.5%–<20% 10-year ASCVD

Recommendation: 1 Consider moderate- to high-intensity statin
LDL-C Goal: Reduce by 30–49% from baseline; target <100 mg/dL
Decision Factors: Presence of risk-enhancing factors, CAC score, patient preference

BORDERLINE RISK: 5%–<7.5% 10-year ASCVD

Recommendation: 2a Consider moderate-intensity statin if risk-enhancing factors present
Risk-Enhancing Factors Support Statin If Present: LDL-C ≥160 mg/dL, hsCRP ≥3 mg/L, Prediabetes, Chronic kidney disease, Family history of premature ASCVD
CAC Scoring Helpful: CAC = 0 may defer therapy; CAC ≥100 favors statin use

LOW RISK: <5% 10-year ASCVD

Recommendation: 1 Emphasis on healthy lifestyle; statin therapy generally not indicated
Exception: Very high LDL-C (≥190 mg/dL) or strong family history of premature ASCVD

LDL-C Reduction Targets by Risk Category

Risk Category LDL Reduction Goal Target LDL-C Intensity
High (≥20%) ≥50% <70 mg/dL High-intensity statin
Intermediate (7.5–<20%) 30–49% <100 mg/dL Moderate to high-intensity statin
Borderline (5–<7.5%) If treated: 30–49% <100 mg/dL Moderate-intensity statin (if initiated)
Low (<5%) Not indicated No specific target Lifestyle alone

Statin Intensity Definitions

High-Intensity

Reduces LDL ≥50%: Atorvastatin 40–80 mg, Rosuvastatin 20–40 mg daily

Moderate-Intensity

Reduces LDL 30–49%: Atorvastatin 10–20 mg, Rosuvastatin 5–10 mg, Pravastatin 40–80 mg daily

Low-Intensity

Reduces LDL <30%: Pravastatin 10–20 mg, Lovastatin 20–40 mg, Simvastatin 5–10 mg daily

Special Populations for Statin Therapy

Statin Dosing & Monitoring

Initial Management Steps:
  1. Measure baseline LDL-C, HDL-C, triglycerides, liver function tests
  2. Initiate statin at target intensity for risk category
  3. Reassess lipids 4–12 weeks after initiation; titrate if LDL goal not met
  4. Consider baseline CK only if symptoms or disease risk (renal impairment, muscle disease)
  5. Monitor for adverse effects: muscle symptoms, liver dysfunction (rare)
  6. Reinforce lifestyle modifications; assess adherence periodically
💡 Pearl: LDL-C reduction, not absolute LDL level, is what matters. A 50% reduction from 200 to 100 mg/dL is high-intensity therapy, even though 100 mg/dL would typically be considered moderate-risk targets.

LDL Reduction Calculator

Estimate LDL percent reduction by statin intensity

Aspirin for Primary Prevention

3 Aspirin should be used infrequently in routine primary prevention of ASCVD. The role of aspirin is limited due to bleeding risk outweighing benefit in lower-risk individuals.

Current Recommendations

Aspirin Indication in Primary Prevention

High-Risk Adults (≥20% 10-year ASCVD): 2a Aspirin may be considered for selected high-risk patients after shared decision-making addressing bleeding risk. Dose: 75–100 mg daily.
Lower-Risk Adults (<20% 10-year): Aspirin is NOT recommended for primary prevention; GI bleeding risk outweighs benefit.
Age Considerations: Benefit in older adults (>70 years) is unclear; bleeding risk increases with age.

Factors Reducing Aspirin Benefit

❌ Don't:

  • Recommend routine aspirin for primary prevention in low- or intermediate-risk individuals
  • Use aspirin as substitute for statin therapy or lifestyle modification
  • Continue aspirin indefinitely without periodic reassessment of risk-benefit
  • Ignore bleeding risk, especially in elderly or those on other anticoagulants

Blood Pressure Management

BP Targets by ASCVD Risk

1 In adults with elevated BP or hypertension, lifestyle modification is first-line, with pharmacotherapy guided by absolute ASCVD risk and BP level.

ASCVD Risk / Population BP Target Class
≥10% 10-year ASCVD risk <130/80 mmHg 1
<10% 10-year ASCVD risk (no other indicators) <140/90 mmHg 1
Chronic kidney disease (eGFR <60) <130/80 mmHg 1
Type 2 Diabetes + Hypertension <130/80 mmHg 1
Elderly without other CV disease <130/80 mmHg 2a (individualize)

Hypertension Thresholds for Pharmacotherapy

When to Initiate Blood Pressure Medication

≥140/90 mmHg (or SBP ≥160, DBP ≥100): 1 Antihypertensive therapy recommended regardless of ASCVD risk
130–<140 mmHg systolic AND ≥10% ASCVD risk: 1 Initiate pharmacotherapy after lifestyle trial (3–6 months)
130–<140 mmHg systolic AND <10% ASCVD risk: 1 Lifestyle modification alone may be sufficient

Antihypertensive Drug Classes (First-Line)

Drug Class Target Dose (Examples) Special Indications / Comments
ACE Inhibitors Lisinopril 10–40 mg daily; Enalapril 10–40 mg daily First-line for diabetes, CKD, post-MI; renal protection
Angiotensin II Receptor Blockers (ARBs) Losartan 50–100 mg daily; Valsartan 80–320 mg daily Similar to ACEi; alternative in ACEi cough; renal protection
Thiazide Diuretics HCTZ 12.5–25 mg daily; Chlorthalidone 12.5–25 mg daily Potent; chlorthalidone longer-acting; caution in hyperglycemia
Calcium Channel Blockers Amlodipine 5–10 mg daily; Diltiazem 120–360 mg daily Well-tolerated; useful in elderly and renal disease
Beta-Blockers Metoprolol 50–200 mg daily; Atenolol 25–100 mg daily Primarily in post-MI or heart failure; less ideal as monotherapy in primary prevention

BP Monitoring & Intensification

Diabetes & Metabolic Syndrome Prevention

Type 2 Diabetes & ASCVD Risk

Individuals with type 2 diabetes are at elevated ASCVD risk. The guideline emphasizes lifestyle optimization combined with glucose-lowering and CV-protective agents.

Lifestyle Interventions for Diabetes

1 For all adults with type 2 diabetes, a tailored nutrition plan and ≥150 minutes per week of moderate-intensity physical activity are recommended.

Pharmacotherapy for Primary Prevention in Type 2 Diabetes

Glucose-Lowering & CV-Protective Agents

First-Line: Metformin

Recommendation: 2a It is reasonable to initiate metformin as first-line therapy along with lifestyle modification
Dose: Start 500 mg daily or BID; titrate to target 1,000–2,000 mg daily in divided doses
Benefit: Modest weight loss (~2 kg), BP reduction, and ~30% ASCVD risk reduction in overweight patients
Monitoring: Check renal function; avoid if eGFR <30 mL/min/1.73m²

GLP-1 Receptor Agonists

Recommendation: 2a For adults with T2DM and additional ASCVD risk factors (age ≥55, prior MI/stroke/PAD, or ≥2 major CV risk factors), GLP-1 RA reduces ASCVD events
Agents: Semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide
Benefit: ~25% ASCVD reduction, modest weight loss (3–5 kg), BP reduction

SGLT2 Inhibitors

Indication: Consider for CV risk reduction and heart failure prevention; empagliflozin, dapagliflozin
Benefit: ~20–30% ASCVD reduction, modest diuresis, BP reduction, HF risk reduction

Metabolic Syndrome & Prediabetes

1 Counseling and comprehensive lifestyle interventions (diet, exercise, weight loss) are recommended for adults with prediabetes to prevent or delay progression to type 2 diabetes.

Condition Definition Intervention
Prediabetes Fasting glucose 100–125 mg/dL OR HbA1c 5.7%–6.4% Intensive lifestyle (DPP model): 150 min/wk activity, 5–7% weight loss, dietary counseling
Metabolic Syndrome ≥3 of: abdominal obesity, elevated BP, elevated glucose, elevated TG, reduced HDL Weight loss (5–10%), physical activity, dietary pattern modification (DASH/Mediterranean)
💡 Pearl: The Diabetes Prevention Program (DPP) showed intensive lifestyle intervention reduced T2DM incidence by 58% and metformin by 31% in prediabetics. Lifestyle changes are powerful.

Special Populations & Considerations

Women

Key Considerations:
  • Risk Calculation: PCE equations account for sex; CV risk in women often clinically underestimated
  • Premature Menopause: Associated with 2-fold increased ASCVD risk; consider risk-enhancing factor in borderline-risk women
  • Pregnancy-Related Risk: Gestational diabetes, preeclampsia increase later ASCVD risk; lifestyle modification important
  • Oral Contraceptives: May increase ASCVD risk, especially with smoking or hypertension; weigh benefits/risks
  • Hormone Replacement Therapy (HRT): Not recommended for ASCVD prevention
  • Lower Risk Thresholds: Women with <7.5% 10-year risk unlikely to benefit from statins unless risk-enhancing factors present

Older Adults (Age ≥75 Years)

Individualized Approach:
  • Statin Initiation: 2b May be considered for primary prevention in select healthy older adults with higher CV risk; benefit less clear in frail patients
  • Risk-Benefit Assessment: Consider life expectancy, functional status, drug interactions, goals of care
  • Deprescribing: If patient tolerating statin poorly, consider discontinuation and focus on lifestyle
  • BP Management: Target <130/80 mmHg reasonable in healthy older adults; individualize in frail patients
  • Medication Interactions: Polypharmacy common; assess for drug–drug interactions

Young Adults (Age 20–39 Years)

Risk Assessment & Prevention:
  • Risk Assessment Timing: 2a Reasonable to assess ASCVD risk factors at least every 4–6 years
  • Risk Calculation: Not standard for <40 years; use if family history or multiple risk factors present
  • Lifestyle Focus: Emphasis on healthy habits: avoid smoking, maintain active lifestyle, healthy diet, weight management
  • Familial Hypercholesterolemia Screening: Consider cascade screening if strong family history

South Asian Ancestry

Enhanced Risk:
  • South Asians have ~2-fold higher ASCVD risk than European ancestry; listed as risk-enhancing factor
  • May consider statin in borderline-risk South Asians more readily
  • Metabolic syndrome and insulin resistance more prevalent; weight and glucose monitoring important

African Americans

Risk & Management:
  • Higher prevalence of hypertension; more aggressive BP control often needed
  • ACE inhibitors or ARBs preferred for hypertension management in those with albuminuria or diabetes
  • Similar statin indications as general population; ensure equitable access to therapy

Clinical Do's & Don'ts

What to DO

✓ DO:

  • Calculate 10-year ASCVD risk for all adults 40–75 years at initial encounter
  • Use absolute risk to guide shared decision-making about preventive therapies
  • Emphasize lifestyle modification (diet, exercise, weight, tobacco) as foundation for all patients
  • Initiate statin therapy for intermediate- and high-risk patients; consider in borderline-risk with risk-enhancing factors
  • Monitor LDL-C response 4–12 weeks after starting statin; adjust dose to achieve goal reduction (%)
  • Individualize BP targets based on ASCVD risk and comorbidities (<130/80 for ≥10% risk; <140/90 for lower risk)
  • Provide pharmacotherapy + counseling for tobacco cessation in all smokers
  • Screen for prediabetes and diabetes; provide lifestyle intervention for prediabetes
  • Address social determinants; ensure equitable access to preventive care and resources
  • Use team-based approach involving physicians, nurses, pharmacists, dietitians, behavioral health specialists

What NOT to DO

✗ DON'T:

  • Prescribe routine aspirin for primary prevention in lower-risk individuals (<20% 10-year risk)
  • Initiate statins without discussion of lifestyle modification—they complement, not replace, behavioral change
  • Ignore risk-enhancing factors in borderline-risk patients; these support treatment consideration
  • Set arbitrary BP or LDL-C targets without considering patient's absolute risk and individual circumstances
  • Skip risk assessment in young adults with family history or multiple risk factors
  • Fail to reassess treatment goals periodically; reprioritize based on changing health status
  • Use only LDL-C levels to guide therapy—focus on percent reduction from baseline
  • Recommend e-cigarettes as smoking cessation aids without evidence of CV benefit
  • Overlook social determinants of health (access, affordability, health literacy)
  • Treat blood pressure or lipids in isolation without comprehensive ASCVD risk reduction

Related Risk Calculators & Tools

Use these interactive tools to support clinical decision-making and patient counseling:

10-Year ASCVD Risk

Calculate 10-year atherosclerotic cardiovascular disease risk using Pooled Cohort Equations (PCE)

PREVENT-ASCVD Risk

Next-generation risk equations incorporating additional risk factors; ages 30–79

Lifetime ASCVD Risk

Estimate risk of developing ASCVD over lifetime for adults 20–59 years

MESA Risk Score

Multi-Ethnic Study of Atherosclerosis risk calculator; addresses diverse populations

Framingham Risk Score

10-year general cardiovascular risk assessment tool

LDL Reduction Calculator

Estimate LDL-C percent reduction and goal LDL by statin intensity

Lp(a) & ASCVD Risk

Assess impact of elevated lipoprotein(a) on ASCVD risk

SCORE2 (European)

European algorithm for 10-year fatal and non-fatal CVD risk

HEART Score

For acute coronary syndrome risk in emergency settings

Key Clinical Pearls

💡 Absolute Risk Rules: Treatment decisions should be based on absolute 10-year ASCVD risk, not just LDL-C or BP numbers. This aligns incentives for patients and clinicians toward overall CV health.
💡 Lifestyle First, Always: Even when pharmacotherapy is indicated, lifestyle modification should be emphasized and reinforced. Statins, blood pressure meds, and other agents complement—not replace—lifestyle change.
💡 Risk-Enhancing Factors Matter: In borderline-risk patients (5%–<7.5% 10-year), the presence of risk-enhancing factors (LDL ≥160, hsCRP ≥3, family history, etc.) tilts the decision-making toward statin initiation after shared discussion.
💡 Percent Reduction, Not Absolute Goals: Focus on achieving ≥50% LDL-C reduction from baseline in high-risk patients, rather than arbitrary absolute LDL targets. A 50% reduction is high-intensity therapy regardless of final LDL level.
💡 Team-Based Care Works: Multidisciplinary teams (physicians, nurses, pharmacists, dietitians) improve medication adherence, lifestyle compliance, and CV outcomes compared to physician-alone approaches.
💡 Social Determinants Influence Outcomes: Socioeconomic status, access to healthy food, transportation, health literacy, and housing stability profoundly affect ASCVD prevention. Tailor recommendations to patient circumstances.
⚠️ Pitfall: Over-relying on LDL-C alone when assessing statin need. A patient with LDL 100 mg/dL but 22% 10-year ASCVD risk requires statin therapy; conversely, LDL 160 mg/dL in a 40-year-old with <5% risk may not.
⚠️ Pitfall: Neglecting lifestyle counseling because patient is "on a statin now." Medication is additive to, not a substitute for, healthy behaviors.
⚠️ Pitfall: Prescribing aspirin routinely in primary prevention. Modern evidence does not support this; bleeding risk often exceeds benefit.